218 related articles for article (PubMed ID: 32569704)
1. Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
Shiraki K; Tan L; Daikoku T; Takemoto M; Sato N; Yoshida Y
Antiviral Res; 2020 Aug; 180():104829. PubMed ID: 32569704
[TBL] [Abstract][Full Text] [Related]
2. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
3. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
4. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
5. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
Shiraki K; Yasumoto S; Toyama N; Fukuda H
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
[TBL] [Abstract][Full Text] [Related]
6. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
Katsumata K; Chono K; Suzuki H
Biochem Pharmacol; 2018 Dec; 158():201-206. PubMed ID: 30365949
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
[TBL] [Abstract][Full Text] [Related]
8. 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.
Spector T; Harrington JA; Morrison RW; Lambe CU; Nelson DJ; Averett DR; Biron K; Furman PA
Proc Natl Acad Sci U S A; 1989 Feb; 86(3):1051-5. PubMed ID: 2536930
[TBL] [Abstract][Full Text] [Related]
9. Ribonucleotide reductase induced by varicella zoster virus. Characterization, and potentiation of acyclovir by its inhibition.
Spector T; Stonehuerner JG; Biron KK; Averett DR
Biochem Pharmacol; 1987 Dec; 36(24):4341-6. PubMed ID: 2825724
[TBL] [Abstract][Full Text] [Related]
10. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.
Earnshaw DL; Bacon TH; Darlison SJ; Edmonds K; Perkins RM; Vere Hodge RA
Antimicrob Agents Chemother; 1992 Dec; 36(12):2747-57. PubMed ID: 1336346
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Chono K; Katsumata K; Suzuki H; Shiraki K
Antiviral Res; 2013 Feb; 97(2):154-60. PubMed ID: 23261844
[TBL] [Abstract][Full Text] [Related]
12. Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1.
Greeley ZW; Giannasca NJ; Porter MJ; Margulies BJ
Antiviral Res; 2020 Apr; 176():104754. PubMed ID: 32114034
[TBL] [Abstract][Full Text] [Related]
13. Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment.
Shiraki K; Takemoto M; Daikoku T
Expert Rev Anti Infect Ther; 2021 Nov; 19(11):1415-1425. PubMed ID: 33853490
[No Abstract] [Full Text] [Related]
14. High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir.
Pacreau ML; Bomme O; Burrel S; Boutolleau D
Antiviral Res; 2021 Nov; 195():105189. PubMed ID: 34666108
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological profiles and clinical effects of amenamevir tablet as treatments for herpes zoster].
Maeda H; Nakamura H; Kikukawa Y
Nihon Yakurigaku Zasshi; 2019; 153(1):35-43. PubMed ID: 30643090
[TBL] [Abstract][Full Text] [Related]
16. Antiviral Drugs Against Alphaherpesvirus.
Shiraki K
Adv Exp Med Biol; 2018; 1045():103-122. PubMed ID: 29896665
[TBL] [Abstract][Full Text] [Related]
17. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
18. Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro.
Heineman TC; Cohen JI
J Virol; 1994 May; 68(5):3317-23. PubMed ID: 8151792
[TBL] [Abstract][Full Text] [Related]
19. Differences in the Likelihood of Acyclovir Resistance-Associated Mutations in the Thymidine Kinase Genes of Herpes Simplex Virus 1 and Varicella-Zoster Virus.
Fujii H; Harada S; Yoshikawa T; Yamada S; Omura N; Shibamura M; Inagaki T; Kato H; Fukushi S; Saijo M
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858222
[TBL] [Abstract][Full Text] [Related]
20. Antiviral effects of Cacicol
Deback C; Rousseau A; Breckler M; Molet L; Boutolleau D; Burrel S; Roque-Afonso AM; Labetoulle M
Antivir Ther; 2018; 23(8):665-675. PubMed ID: 30028308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
